Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04592913
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : August 3, 2022
Information provided by (Responsible Party):